Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1&#x03B1; inhibition, and hypoxia-activated chemotherapy

Changhwan Yoon; Kevin K. Chang; Jun Ho Lee; William D. Tap; Charles P. Hart; M. Celeste Simon; Sam S. Yoon

doi:10.18632/oncotarget.28560

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Retraction:

Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy

PDF | How to cite

Oncotarget. 2024; 15:123-123. https://doi.org/10.18632/oncotarget.28560

Metrics: PDF 379 views | ?

Changhwan Yoon¹, Kevin K. Chang¹, Jun Ho Lee¹, William D. Tap², Charles P. Hart³, M. Celeste Simon⁴ and Sam S. Yoon¹

¹Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
²Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
³Threshold Pharmaceuticals, South San Francisco, CA, USA
⁴Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Published: February 08, 2024

Copyright: © 2024 Yoon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: Oncotarget has completed its investigation of this paper. A concerned reader informed the journal of several instances of image duplication. Namely, there is internal duplication between two images in Figure 3C. In addition, two images in Figure 3C are duplicates of images in Figure 6F from a previously published paper [1]. There is also a second internal duplication of one image in both Figures 4B and 6B. In light of these issues, the journal requested clarification regarding these images from the authors. The provided explanations were deemed unacceptable by the Scientific Integrity Office. Based on these facts, Oncotarget has decided to retract this paper.

REFERENCES

1. Yoon C, Lee HJ, Park DJ, Lee YJ, Tap WD, Eisinger-Mathason TS, Hart CP, Choy E, Simon MC, Yoon SS. Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas. Br J Cancer. 2015; 113:46–56. https://doi.org/10.1038/bjc.2015.186. [PubMed]

Original article: Oncotarget. 2016; 7:42844–42858. DOI: https://doi.org/10.18632/oncotarget.10212

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28560

Publication Alerts

Retraction:

Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy